A single infusion of ketamine improves depression scores in patients with anxious bipolar depression
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: Patents with anxious bipolar disorder have worse clinical outcomes and are harder to treat with traditional medication regimens compared to those with non‐anxious bipolar disorder. Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder. We sought to determine whether baseline anxiety status reduced ketamine's ability to decrease symptoms of depression. Methods: Thirty‐six patients with anxious (n = 21) and non‐anxious (n = 15) treatment‐resistant bipolar depression (types I and II; concurrently treated with either lithium or valproate) received a single infusion of ketamine (0.5 mg/kg) over 40 min. Post‐hoc analyses compared changes in the Montgomery–Åsberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HDRS) in anxious versus non‐anxious depressed patients with bipolar disorder through 14 days post‐infusion. Anxious bipolar depression was defined as DSM‐IV bipolar depression plus a HDRS Anxiety/Somatization Factor score of ≥ 7. Results: A linear mixed model revealed a significant effect of anxiety group on the MADRS (p = 0.04) and HDRS (p = 0.04). Significant drug effects (all p < 0.001) suggested that both anxious and non‐anxious groups had an antidepressant response to ketamine. The drug‐by‐anxiety interactions were not significant (all p > 0.28). Conclusions: Both anxious and non‐anxious patients with bipolar depression had significant antidepressant responses to ketamine, although the anxious depressed group did not show a clear antidepressant response disadvantage over the non‐anxious group. Given that anxiety has been shown to be a predictor of poor treatment response in bipolar depression when traditional treatments are used, our findings suggest a need for further investigations into ketamine's novel role in the treatment of anxious bipolar depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 4×
“5 mg/kg over 40 minutes) has been shown to have a rapid (within 40 minutes) and robust antidepressant effect when given to moderately-toseverely depressed patients with bipolar disorder (despite having failed multiple medications trials) maintained on therapeutic levels of lithium or valproate; this effect lasted thro…”
InfluentialSelf-citationBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 1×
“The Clinician Administered Dissociative States Scale (CADSS) was used as a secondary outcome measure for side effects (22).”
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 4×
“Indeed, ketamine has been shown to rapidly and robustly reduce symptoms of depression in a sample of patients with treatment-resistant bipolar disorder (with and without anxiety) (13, 14).”
InfluentialSelf-citationDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 1×
“Indeed, ketamine has been shown to rapidly and robustly reduce symptoms of depression in a sample of patients with treatment-resistant bipolar disorder (with and without anxiety) (13, 14).”
Self-citationAnxiety as a Correlate of Response to the Acute Treatment of Bipolar I Disorder
Feske, U. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.956 · Cited by 230 · cited 6×
“Similarly, another study found non-remission in bipolar disorder to be associated with current or past anxiety symptoms, as well as a history of panic attacks, more severe depression, and a greater number of past depressive or manic episodes (3).”
InfluentialAnxious and non-anxious bipolar disorder
Trevor Young, L., Cooke, R. G., Robb, J. C., Levitt, A. J., & Joffe, R. T. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90118-4 · Cited by 178 · cited 6×
“This anxious subtype of bipolar disorder is common, with a prevalence of approximately 25–50% in some studies (3, 4).”
InfluentialDefining anxious depression: a review of the literature
Ionescu, D. F., Niciu, M. J., Henter, I. D., & Zarate, C. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000114 · Cited by 119
Self-citationEffect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., Slonena, E. E., Vande Voort, J. L., Brutsche, N. E., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09049 · Cited by 111
Self-citationRandomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69 · cited 2×
“Similarly, ziprasidone monotherapy did not significantly improve anxiety symptoms in patients with bipolar disorder with comorbid panic disorder or GAD; instead, it was associated with more negative side effects versus placebo (6).”
Suppes, T., McElroy, S. L., Sheehan, D. V., Hidalgo, R. B., Cosgrove, V. E., Gwizdowski, I. S., & Feldman, N. S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08297 · Cited by 22 · cited 1×
“Similarly, ziprasidone monotherapy did not significantly improve anxiety symptoms in patients with bipolar disorder with comorbid panic disorder or GAD; instead, it was associated with more negative side effects versus placebo (6).”
Research works printed but not linked: 16
- 10.1176/appi.books.9780890425596 · DOI · Paper page
- 10.1007/s11126-008-9071-5 · DOI
- 10.2147/DDDT.S63779 · DOI · Paper page
- 10.1016/j.jad.2007.03.014 · DOI · Paper page
- 10.1176/appi.ajp.2013.13070984 · DOI · Paper page
- 10.1176/appi.ajp.2013.13070985 · DOI · Paper page
- 10.1016/j.jad.2011.12.001 · DOI
- First MB, 1997, Structured Clinical Interview for DSM‐IV Axis I Disorders (SCID I)
- 10.1192/bjp.134.4.382 · DOI · Paper page
- Cleary P, 1977, Factor analysis of Hamilton Depression Scale, Drugs Exp Clin Res, 1, 115
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- American Psychiatric Association, 2000, Task Force on DSM‐IV. Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV‐TR
- 10.1002/mpr.353 · DOI · Paper page
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- 10.1176/appi.ajp.2014.13101434 · DOI
- 10.4088/JCP.13m08961 · DOI · Paper page
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“60,61 More recently, an intranasal form of esketamine (a ketamine enantiomer) has been developed, which has shown good effect with continued treatment in combination with an oral antidepressant 26 and has now been approved by the FDA for restricted use in TRD.”
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citationBahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Metadata
- Authors
- Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2014-11-14
- Volume
- 17
- Issue
- 4
- Pages
- 438-443
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2043085142
- Cited by
- 104
- References
- 10
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- NARSAD (Independent Investigator to CAZ)
- National Institute of Mental Health (Intramural Research Program to CAZ)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. https://app.cochat.ai/papers/10.1111/bdi.12277
- The paper
- Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2015). A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders. https://doi.org/10.1111/bdi.12277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.